#Japan #Tokyo #Sysmex #Vetanic #Kohjin Bio

Vetanic Partners with Sysmex and Kohjin Bio for Animal Regenerative Medicine

Kyoto, Japan – Leading regenerative veterinary medicine company Vetanic has recently finalized a capital and business alliance with Sysmex Corporation and Kohjin Bio Co., Ltd., aiming to push the frontiers of animal regenerative medicine utilizing iPS cell technology.

Background and Objectives of the Partnership

Vetanic, headquartered in Minato, Tokyo, has been conducting cutting-edge research and development in the field of veterinary medicine using induced pluripotent stem (iPS) cells. iPS cells, which are artificially created multipotent stem cells from adult tissue, have vast potential for generating various types of tissues. The technology was pioneered by Professor Shinya Yamanaka and led him to win the Nobel Prize in Physiology or Medicine in 2012.

Sysmex, based in Kobe, Hyogo, stands out as a global leader in clinical testing grounded in advanced analytical techniques. Their expertise extends beyond human healthcare into veterinary medicine, where they excel in cell evaluation and quality management in the regenerative medicine domain. The collaboration with Vetanic will leverage their capabilities in the automation of cell manufacturing through robotics technology.

Kohjin Bio, headquartered in Saitama, has reinforced its position in the regenerative medicine market with a focus on custom media development and an extensive supply network for related materials. By collaborating with Vetanic, Kohjin Bio aims to further enhance the product development landscape in the animal healthcare sector. This partnership officially began in November 2024.

Strategic Implementation

By executing a third-party allocation of shares with both companies, Vetanic intends to strengthen its capital structure and exploit the complementary strengths of each partner. The collaboration aims to accelerate the following initiatives:

• - Development and enhancement of quality evaluation technologies for cell therapy (iMSC) products.
• - Establishment and scaling of manufacturing processes and supply chains.
• - Promotion of translational medicine bridging veterinary and human healthcare based on the One Health concept.

Benefits of the Partnership

This strategic alliance offers Vetanic not only capital support but also valuable synergies by integrating technological advancements from both partners:

• - Development of animal cell evaluation systems utilizing Sysmex’s analytical technologies.
• - Advancement in high-quality regenerative medicine products using Kohjin Bio’s cell culture media and materials.
• - Creation of new business opportunities through joint projects concerning culture supernatants and alternatives to animal testing.

Future Prospects

Through this capital and business alliance, Vetanic aims to strengthen the entire value chain from research and development to manufacturing, quality control, and commercialization. They aspire to provide innovative treatment options centered on iPS cell-derived high-quality regenerative medicine for animals, with a specific focus on dogs, cats, and horses.

The collaboration also seeks to develop alternative testing methods using iPS cell-derived various cells, paving the way for potential expansions into human medical domains. By enhancing competitiveness in the global market, Vetanic aims to elevate its corporate value significantly.

Understanding iPS Cells

Induced pluripotent stem cells (iPS cells) are a breakthrough in medical science, allowing for the creation of pluripotent stem cells from differentiated adult cells. Their potential applications in regenerative medicine are transforming how diseases are treated, having already resulted in approvals for human iPS cell-derived products in Japan.

Understanding Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells capable of secreting various anti-inflammatory substances. Their applications in regenerative medicine are expanding, with existing MSC products demonstrating efficacy in treating serious diseases. Importantly, iPS cell-derived MSCs eliminate donor dependency and offer a higher degree of uniformity, positioning themselves as a promising solution for future therapies.

About Vetanic

Vetanic was established in January 2021 as a startup venture based on clinical applications of animal iPS cell technology. The company’s mission is to offer sustainable, donor-free regenerative medicine products developed from iPS cells of dogs, cats, and horses, leading towards a global standard in veterinary regenerative medicine. For more information, visit www.vetanic.com.

About Sysmex Corporation

Sysmex Corporation has been dedicated to advancing healthcare since its inception in 1968, creating innovative solutions focused on clinical assays for blood and urine tests. It operates in over 190 countries, supporting health across populations. Their commitment to innovation drives a long-term vision for improving healthcare journeys for individuals worldwide. Explore more at www.sysmex.co.jp.

About Kohjin Bio

Founded in April 1981, Kohjin Bio specializes in the manufacture and sale of culture media for cellular applications and medical diagnostics. As the global regenerative medicine market expands, the company focuses on developing culture solutions while pursuing new opportunities both domestically and internationally. Learn more at www.kohjin-bio.jp.

For Inquiries

Contact: Vetanic
Email: [email protected]